Investigadora del grupo de Neurobiología de la Audición participa en un ensayo clínico de un nuevo tratamiento para el angioedema hereditario

A researcher from the Neurobiology of Hearing group participates in a clinical trial of a new treatment for hereditary angioedema

Dr. Maria Luisa Baeza from the Neurobiology of Hearing group has participated in a Phase III clinical study ((EudraCT 2013-000916-10, NCT01912456) to evaluate the efficacy and safety of the C-1 inhibitor CSL830 in the treatment of hereditary angioedema The results of this trial indicate that the subcutaneous administration of CSL830 decreases the number of attacks of hereditary angioedema per month, with the majority of patients presenting a low profile of side effects. This work has been published in the prestigious New England Journal of Medicine

Longhurst et al. Prevention of Hereditary Angioedema Attacks with Subcutaneous C1-Inhibitor. NEJM 2017 Mar 23;376(12):1131-1140